Scilex Holding SCLX 深 滬
等待開盤 09-19 09:30:00 美东时间
25.66
+0.700
+2.80%
華盛通- 最 高25.98
- 今 開25.01
- 成交量 7.73万股
- 最 低 24.60
- 昨 收 24.96
- 總市值 1.41亿
- 52周最高 39.90
- 市盈率 靜 --
- 換手率 1.41%
- 52周最低 3.60
- 委 比 -0.50%
- 總股本 549.74万
- 歷史最高 591.50
- 量 比 0.32
- 振 幅 5.53%
- 歷史最低 0.00
- 每 手 1
- 風險率 9.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Semnur Pharmaceuticals, A Majority-Owned Subsidiary Of Scilex Holding Company Announces That Shareholders Of Denali Capital Acquisition Corp Have Approved The Previously Announced Business Combination With Semnur; Financial Terms Not Disclosed
Semnur Pharmaceuticals, Inc. ("Semnur"), a majority-owned subsidiary of Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and
09-04 21:05
Scilex CEO to resign as focus turns to Semnur – Denali merger
Scilex Holding (NASDAQ:SCLX) announced on Thursday that its CEO, Jaisim Shah, would resign and continue to lead its majority-owned subsidiary Semnur Pharmaceuticals, which has signed a merger agreemen...
08-21 18:57
Scilex Holding Q2 EPS $(7.42) Misses $(0.91) Estimate, Sales $9.896M Miss $26.250M Estimate
Scilex Holding (NASDAQ:SCLX) reported quarterly losses of $(7.42) per share which missed the analyst consensus estimate of $(0.91) by 715.38 percent. This is a 31.61 percent increase over losses of $(10.85) per share
08-14 15:42
Scilex Moves Closer to Semnur Merger as SEC Clears Registration for Denali Acquisition Vote in September
Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX) , an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of
08-13 18:05
Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex
Denali's Form S-4 registration statement has been approved by the SEC, enabling the proposed business combination with Semnur. The extraordinary general meeting of Denali shareholders to vote on this transaction is scheduled for September 3, 2025. Upon completion, the combined entity will operate as Semnur Pharmaceuticals, Inc. Scilex Holding Company, the parent of Semnur, specializes in non-opioid pain management solutions and has a diverse port...
08-13 10:00
美股牛股 | 公司获高额股权融资，VWAV飙涨近370%；CELC大涨超167%
公司获高额股权融资，VWAV飙涨近370%；乳腺癌药物实验效果积极，CELC大涨超167%；正式进军稳定币领域，MPU大涨超40%>>
07-29 19:19
Oramed Grants Scilex $27M Option To Repurchase Warrants, With Potential Note Extension To 2026
As previously disclosed, on September 21, 2023, Oramed Pharmaceuticals Inc. (the "Company") entered into and consummated the transactions contemplated by a Securities Purchase Agreement (as amended by that certain
07-23 21:47
Scilex Holding Company Concludes 2025 Annual Stockholders Meeting
An announcement from Scilex Holding Company ( ($SCLX) ) is now available. On Ju...
06-24 04:37
Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board
Scilex Holding Company, headquartered in Palo Alto, California, announced that its Board of Directors has deferred the previously announced record date of May 2, 2025, for its preferred stock dividend to stockholders. The new record date will be determined at the Board's discretion, with the right to change or revoke the dividend. Scilex focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chroni...
06-23 20:50
Scilex Holding Announces Publication On GLOPERBA Dosing Adjustments In Peer-Review Journal
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute
06-06 00:10
